← SynDRA
PF-06459988
SynDRA canonical compound SYN0038546 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | EGFR |
|---|
| Mechanism of action | receptor tyrosine protein kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- receptor tyrosine protein kinase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Cross-references
Synonyms
- 5IE92SK9EB
- RefChem:172256
- Mutant-selective EGFR Inhibitor PF-06459988
- UNII-5IE92SK9EB
- MFCD28987462
- orb1307899
- SCHEMBL14800837
- SCHEMBL29378347
- DHC77445
- EX-A2705
- BDBM50159360
- NSC810341
- AKOS040742401
- EBC-498111
- NSC-810341
- HY-19985
- MS-27695
- CS-0017709
- G14590
- PF-06459988?
- T16492
- PF-06459988, >=98% (HPLC)
- 1-[(3R,4R)-3-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxymethyl]-4-methoxypyrrolidin-1-yl]prop-2-en-1-one
Look up PF-06459988 in the interactive SynDRA portal →